A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Trial details
- Registry ID
- NCT05357950
- Drugs studied
- PrimeC
TrialRedline tracks 2 clinical trials sponsored by NeuroSense Therapeutics Ltd.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALSNCT05357950 | PrimeC | Completed | 2023-11-02Actual |
| A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.NCT06185543 | PrimeC | Terminated | 2025-09-30Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 20 participants (planned). After: 8 participants (actual).
Before: Estimated. After: Actual.
Before: Nov 2025. After: 30 Sep 2025.
Before: Recruiting. After: Terminated.